Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK Inhibitor–Pretreated R/R MCL
OncLive,
Jonathon B. Cohen, MD, MS Longer follow-up of the phase 1/2 BRUIN study (NCT03740529) continues to demonstrate the tolerability…
Pirtobrutinib Shows Promising Efficacy in R/R Mantle Cell Lymphoma
Cancer Network,
“For many of us, [pirtobrutinib] a new standard of care for patients who have received a prior covalent BTK inhibitor,…
Pirtobrutinib Displays Activity in Relapsed/Refractory MCL Following Covalent BTK Inhibitor Therapy
OncLive,
Jonathon B. Cohen, MD, MS The highly-selective, non-covalent BTK inhibitor pirtobrutinib (Jaypirca) demonstrated promising…